DOCSLIB.ORG

Genetics of Acromegaly and Gigantism

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetics of Acromegaly and Gigantism Journal of Clinical Medicine Review Genetics of Acromegaly and Gigantism Anna Bogusławska 1 and Márta Korbonits 2,* 1 Department of Endocrinology, Jagiellonian University Medical College, 31-008 Cracow, Poland; [email protected] 2 Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London EC1M 6BQ, UK * Correspondence: [email protected] Abstract: Growth hormone (GH)-secreting pituitary tumours represent the most genetically de- termined pituitary tumour type. This is true both for germline and somatic mutations. Germline mutations occur in several known genes (AIP, PRKAR1A, GPR101, GNAS, MEN1, CDKN1B, SDHx, MAX) as well as familial cases with currently unknown genes, while somatic mutations in GNAS are present in up to 40% of tumours. If the disease starts before the fusion of the epiphysis, then accelerated growth and increased final height, or gigantism, can develop, where a genetic background can be identified in half of the cases. Hereditary GH-secreting pituitary adenoma (PA) can manifest as isolated tumours, familial isolated pituitary adenoma (FIPA) including cases with AIP mutations or GPR101 duplications (X-linked acrogigantism, XLAG) or can be a part of systemic diseases like multiple endocrine neoplasia type 1 or type 4, McCune–Albright syndrome, Carney complex or phaeochromocytoma/paraganglioma-pituitary adenoma association. Family history and a search for associated syndromic manifestations can help to draw attention to genetic causes; many of these are now tested as part of gene panels. Identifying genetic mutations allows appropriate screening of associated comorbidities as well as finding affected family members before the clinical manifestation of the disease. This review focuses on germline and somatic mutations predisposing to acromegaly Citation: Bogusławska, A.; and gigantism. Korbonits, M. Genetics of Acromegaly and Gigantism. J. Clin. Med. 2021, 10, Keywords: acromegaly; AIP; gigantism; FIPA; MEN1; somatotroph adenoma; pituitary neuroen- 1377. https://doi.org/10.3390/ docrine tumour; X-linked acrogigantism jcm10071377 Academic Editor: Shereen Ezzat 1. Introduction Received: 10 February 2021 Acromegaly is a rare, chronic disorder caused by excessive growth hormone (GH) Accepted: 19 March 2021 production. Common clinical manifestations include changes in appearance, headache, Published: 29 March 2021 joint pains as well as serious systemic complications such as metabolic, cardiovascular and osteoarticular comorbidities especially axial arthritis and higher risk of tumour growth Publisher’s Note: MDPI stays neutral (e.g., colon polyps and thyroid nodules) [1]. Cardiovascular diseases and cancer are mostly with regard to jurisdictional claims in responsible for an increased mortality in untreated patients [2,3]. Due to complications, published maps and institutional affil- quality of life is significantly reduced [4]. In childhood and adolescence, an excessive iations. GH secretion before complete epiphyseal closure leads to gigantism, characterised by abnormally tall stature. The prevalence of acromegaly is estimated between 28 to 137 per million people [5]. In most studies, females are slightly more (1:1.24) affected than males and the peak age of diagnosis is within the 5th decade of life [3,5]. The most common Copyright: © 2021 by the authors. cause of acromegaly and gigantism is growth hormone (GH) secreting pituitary adenoma Licensee MDPI, Basel, Switzerland. (PA), also called pituitary neuroendocrine tumour (PitNET) (Box1), which represents This article is an open access article approximately 9–13% of all PAs. distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). J. Clin. Med. 2021, 10, 1377. https://doi.org/10.3390/jcm10071377 https://www.mdpi.com/journal/jcm J. Clin. Med. 2021, 10, 1377 2 of 24 Box 1. Pituitary neuroendocrine tumour (PitNET). In 2017 The International Pituitary Pathology Club suggested that the hormone-producing cells of the pituitary are a part of the neuroendocrine system and sometimes show invasive growth, therefore, proposed to use the phrase pituitary neuroendocrine tumour (PitNET) rather than pituitary adenoma, to highlight the similarity with other neuroendocrine neoplasms [6]. This suggestion has been met with some controversy [7–9]. It was suggested that there is a risk that aligning adenohypophyseal tumours to other neuroendocrine tumours would raise unnecessary anxiety in patients and physicians less familiar with the disease, and for the time being suggested to carry on using the term adenoma with further discussion invited on this issue [10]. As PitNET is a valid term, in a scientific publication its use can be deemed appropriate. We acknowledge that both terms have advantages and disadvantages, and will use both terms in the review. Pituitary hyperplasia is encountered less commonly, mainly as part of genetic dis- orders such as Carney complex (CNC), McCune–Albright syndrome (MAS) or X-linked acrogigantism (XLAG). In rare cases (less than 1%), neuroendocrine tumours producing growth hormone releasing hormone (GHRH) or ectopic GH-secreting tumours have been described [11–13]. Altered growth hormone regulation resulting in GH excess can ac- company neurofibromatosis type 1, associated with optic pathway gliomas (OPG) [14]. Additionally, deficiency in the immunoglobulin superfamily member 1 (IGSF1), may result in somatotroph neurosecretory hyperfunction in adults [15]. Most somatotroph PitNETs develop sporadically; however, in nearly 46–49% of gi- gantism, the identifiable genetic background has been reported [16,17]. Hereditary GH- secreting pituitary tumours can manifest as an isolated manifestation, called familial isolated pituitary adenoma (FIPA), due to either loss-of-function mutations in aryl hy- drocarbon receptor interacting protein (AIP) or due to gain-of-function gene duplication in GPR101, causing XLAG. Hereditary pituitary tumours can also be part of syndromic disease accompanied by other manifestations, often tumours of other endocrine organs, such as in multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 4 (MEN4), MAS, CNC, or phaeochromocytoma/paraganglioma (PPGL)-pituitary adenoma association [18–25] (Table1). J. Clin. Med. 2021, 10, 1377 3 of 24 Table 1. Germline and somatic GNAS mutations associated with acromegaly and gigantism (adapted from Gadelha et al. [26]). Gene Muta- Prevalence in Pituitary Prevalence in Mean Age of Diagnosis of Disease tion/Genetic Gene Location Phenotype Histopathology Tumours Acromegaly (%) GH Excess Alteration 50% in homogeneous FIPA More often 2nd decade of life (<30 4% in sporadic sparsely FIPA/AIP AIP 11q13.3 3.6% Isolated pituitary tumour years), male predominance, acromegaly granulated reduced SSTR 2 expression 29% in gigantism variant patients Often first years of life (<5 years) 0–4.4% in somatotroph female predominance, FIPA/X-linked acromegaly h/lactotroph GPR101 Xq26.3 1.6% Isolated pituitary tumour pituitary hyperplasia or acrogigantism 10% of gigantism pituitary tumour, males can be mosaic patients hyperplasia in or familial 25% of cases Multiple PAs and more often plurihormonal profile. More Hyperparathyroidism, Multiple 1.2% in acromegaly often pituitary pituitary tumour, 4th decade of life Endocrine MEN1 11q13.1 0.6–2.6% 1% of gigantism hyperplasia. In pancreatic female predominance Neoplasia type 1 patients some part of neuroendocrine tumours patients, poorly- differentiated PIT1- lineage tumours Hyperparathyroidism, Multiple More often pituitary tumour, Endocrine CDKN1B 12p13.1 rare rare Single cases pituitary pancreatic Neoplasia type 4 hyperplasia neuroendocrine tumours Classic triad: fibrosus 2nd decade of life McCune– More often Mosaic GNAS Only acromegaly/gigantism 5% of gigantism dysplasia, cafe- au-lait male predominance, Albright 20q13.3 pituitary mutation (20% of patients) patients macules, precocious pituitary hyperplasia, Syndrome hyperplasia puberty prolactin cosecretion somatotroph PRKAR1A 17q22-24 Only acromegaly/gigantism 1% among Acromegaly, cardiac and 3rd decade of life no gender Carney Complex h/lactotroph (12% but 75% asymptomatic gigantism patients cutaneous myxomas, predominance, hyperplasia pituitary CNC2 locus 2p16 elevation of GH and IGF-1 PPNAD, lentiginosis (majority) or tumour hyperplasia J. Clin. Med. 2021, 10, 1377 4 of 24 Table 1. Cont. Gene Muta- Prevalence in Pituitary Prevalence in Mean Age of Diagnosis of Disease tion/Genetic Gene Location Phenotype Histopathology Tumours Acromegaly (%) GH Excess Alteration SDHx SDHA 5p15.33 VHL Pituitary SDHB 1p36.13 Association between intracytoplasmic MEN1 Single cases adenoma and SDHC 1q23.3 rare rare PPGL and pituitary vacuoles RET PPGL association SDHD 11q23.1 tumour MAX 14q23.3 Neurofibromas, cafe Only acromegaly/gigantism- Neurofibromatosis au-lait macules, No visible pituitary NF1 17q11.2 around 10% in patients with rare - type 1 freckling, Lisch nodules, pathology NF1 and optic glioma optic glioma Deficiency of the X-link acromegalic facial No visible pituitary immunoglobulin IGSF1 Xq26.1 Only GH excess features Not estimated features organomegaly - pathology superfamily in adulthood member 1 no association has been smaller size, good response observed Sporadic soma- Somatic GNAS 20q13.3 Only acromegaly 40% Isolated pituitary tumour to medical treatment with between GNAS totropinomas mutation somatostatin analogues
Load more

Recommended publications
  • GH/IGF-1 Abnormalities and Muscle Impairment: from Basic Research to Clinical Practice
    International Journal of Molecular Sciences Review GH/IGF-1 Abnormalities and Muscle Impairment: From Basic Research to Clinical Practice Betina Biagetti * and Rafael Simó * Diabetes and Metabolism Research Unit, Vall d’Hebron Research Institute and CIBERDEM (ISCIII), Universidad Autónoma de Barcelona, 08193 Bellaterra, Spain * Correspondence: [email protected] (B.B.); [email protected] (R.S.); Tel.: +34-934894172 (B.B.); +34-934894172 (R.S.) Abstract: The impairment of skeletal muscle function is one of the most debilitating least understood co-morbidity that accompanies acromegaly (ACRO). Despite being one of the major determinants of these patients’ poor quality of life, there is limited evidence related to the underlying mechanisms and treatment options. Although growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels are associated, albeit not indisputable, with the presence and severity of ACRO myopathies the precise effects attributed to increased GH or IGF-1 levels are still unclear. Yet, cell lines and animal models can help us bridge these gaps. This review aims to describe the evidence regarding the role of GH and IGF-1 in muscle anabolism, from the basic to the clinical setting with special emphasis on ACRO. We also pinpoint future perspectives and research lines that should be considered for improving our knowledge in the field. Keywords: acromegaly; myopathy; review; growth hormone; IGF-1 1. Introduction Acromegaly (ACRO) is a rare chronic disfiguring and multisystem disease due to Citation: Biagetti, B.; Simó, R. non-suppressible growth hormone (GH) over-secretion, commonly caused by a pituitary GH/IGF-1 Abnormalities and Muscle tumour [1].
    [Show full text]
  • Lymphocytic Hypophysitis Successfully Treated with Azathioprine
    1581 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.74.11.1581 on 14 November 2003. Downloaded from SHORT REPORT Lymphocytic hypophysitis successfully treated with azathioprine: first case report A Lecube, G Francisco, D Rodrı´guez, A Ortega, A Codina, C Herna´ndez, R Simo´ ............................................................................................................................... J Neurol Neurosurg Psychiatry 2003;74:1581–1583 is not well established, but corticosteroids have been An aggressive case of lymphocytic hypophysitis is described proposed as first line treatment.10–12 Trans-sphenoidal surgery which was successfully treated with azathioprine after failure should be undertaken in cases associated with progressive of corticosteroids. The patient, aged 53, had frontal head- mass effect, in those in whom radiographic or neurological ache, diplopia, and diabetes insipidus. Cranial magnetic deterioration is observed during treatment with corticoster- resonance imaging (MRI) showed an intrasellar and supra- oids, or when it is impossible to establish the diagnosis of sellar contrast enhancing mass with involvement of the left lymphocytic hypophysitis with sufficient certainty.25 cavernous sinus and an enlarged pituitary stalk. A putative We describe an unusually aggressive case of pseudotumor- diagnosis of lymphocytic hypophysitis was made and ous lymphocytic hypophysitis successfully treated with prednisone was prescribed. Symptoms improved but azathioprine. This treatment was applied empirically because recurred after the dose was reduced. Trans-sphenoidal of the failure of corticosteroids. To the best to our knowledge, surgery was attempted but the suprasellar portion of the this is the first case of lymphocytic hypophysitis in which mass could not be pulled through the pituitary fossa. such treatment has been attempted. The positive response to Histological examination confirmed the diagnosis of lympho- azathioprine suggests that further studies should be done to cytic hypophysitis.
    [Show full text]
  • Acromegaly Remission, SIADH and Pituitary Function Recovery After Macroadenoma Apoplexy
    ID: 19-0057 -19-0057 E Sanz-Sapera and others Apoplexy and remission of ID: 19-0057; July 2019 acromegaly DOI: 10.1530/EDM-19-0057 Acromegaly remission, SIADH and pituitary function recovery after macroadenoma apoplexy Correspondence should be addressed E Sanz-Sapera1, S Sarria-Estrada2, F Arikan3 and B Biagetti1 to B Biagetti Email 1Endocrinology, 2Radiology, and 3Neurosurgery, Vall d’Hebron Hospital, Barcelona, Spain [email protected] Summary Pituitary apoplexy is a rare but potentially life-threatening clinical syndrome characterised by ischaemic infarction or haemorrhage into a pituitary tumour that can lead to spontaneous remission of hormonal hypersecretion. We report the case of a 50-year-old man who attended the emergency department for sudden onset of headache. A computed tomography(CT)scanatadmissionrevealedpituitaryhaemorrhageandthebloodtestconfirmedtheclinicalsuspicionof acromegaly and an associated hypopituitarism. The T1-weighted magnetic resonance imaging (MRI) showed the classic pituitary ring sign on the right side of the pituitary. Following admission, he developed acute-onset hyponatraemia that required hypertonic saline administration, improving progressively. Surprisingly, during the follow-up, IGF1 levels became normal and he progressively recovered pituitary function. Learning points: • Patients with pituitary apoplexy may have spontaneous remission of hormonal hypersecretion. If it is not an emergency, we should delay a decision to undertake surgery following apoplexy and re-evaluate hormone secretion. • Hyponatraemia is an acute sign of hypocortisolism in pituitary apoplexy. However, SIADH although uncommon, could appear later as a consequence of direct hypothalamic insult and requires active and individualised treatment.Forthisreason,closelymonitoringsodiumatthebeginningoftheepisodeandthroughoutthefirst week is advisable to guard against SIADH. • Despite being less frequent, if pituitary apoplexy is limited to the tumour, the patient can recover pituitary function previously damaged by the undiagnosed macroadenoma.
    [Show full text]
  • Lower Genomic Stability of Induced Pluripotent Stem Cells Reflects
    Zhang et al. Cancer Commun (2018) 38:49 https://doi.org/10.1186/s40880-018-0313-0 Cancer Communications ORIGINAL ARTICLE Open Access Lower genomic stability of induced pluripotent stem cells refects increased non‑homologous end joining Minjie Zhang1,2†, Liu Wang3†, Ke An1,2†, Jun Cai1, Guochao Li1,2, Caiyun Yang1, Huixian Liu1, Fengxia Du1, Xiao Han1,2, Zilong Zhang1,2, Zitong Zhao1,2, Duanqing Pei4, Yuan Long5, Xin Xie5, Qi Zhou3 and Yingli Sun1* Abstract Background: Induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) share many common features, including similar morphology, gene expression and in vitro diferentiation profles. However, genomic stability is much lower in iPSCs than in ESCs. In the current study, we examined whether changes in DNA damage repair in iPSCs are responsible for their greater tendency towards mutagenesis. Methods: Mouse iPSCs, ESCs and embryonic fbroblasts were exposed to ionizing radiation (4 Gy) to introduce dou- ble-strand DNA breaks. At 4 h later, fdelity of DNA damage repair was assessed using whole-genome re-sequencing. We also analyzed genomic stability in mice derived from iPSCs versus ESCs. Results: In comparison to ESCs and embryonic fbroblasts, iPSCs had lower DNA damage repair capacity, more somatic mutations and short indels after irradiation. iPSCs showed greater non-homologous end joining DNA repair and less homologous recombination DNA repair. Mice derived from iPSCs had lower DNA damage repair capacity than ESC-derived mice as well as C57 control mice. Conclusions: The relatively low genomic stability of iPSCs and their high rate of tumorigenesis in vivo appear to be due, at least in part, to low fdelity of DNA damage repair.
    [Show full text]
  • HYPOPITUITARISM YOUR QUESTIONS ANSWERED Contents
    PATIENT INFORMATION HYPOPITUITARISM YOUR QUESTIONS ANSWERED Contents What is hypopituitarism? What is hypopituitarism? 1 What causes hypopituitarism? 2 The pituitary gland is a small gland attached to the base of the brain. Hypopituitarism refers to loss of pituitary gland hormone production. The What are the symptoms and signs of hypopituitarism? 4 pituitary gland produces a variety of different hormones: 1. Adrenocorticotropic hormone (ACTH): controls production of How is hypopituitarism diagnosed? 6 the adrenal gland hormones cortisol and dehydroepiandrosterone (DHEA). What tests are necessary? 8 2. Thyroid-stimulating hormone (TSH): controls thyroid hormone production from the thyroid gland. How is hypopituitarism treated? 9 3. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH): LH and FSH together control fertility in both sexes and What are the benefits of hormone treatment(s)? 12 the secretion of sex hormones (estrogen and progesterone from the ovaries in women and testosterone from the testes in men). What are the risks of hormone treatment(s)? 13 4. Growth hormone (GH): required for growth in childhood and has effects on the entire body throughout life. Is life-long treatment necessary and what precautions are necessary? 13 5. Prolactin (PRL): required for breast feeding. How is treatment followed? 14 6. Oxytocin: required during labor and delivery and for lactation and breast feeding. Is fertility possible if I have hypopituitarism? 15 7. Antidiuretic hormone (also known as vasopressin): helps maintain normal water Summary 15 balance. What do I need to do if I have a pituitary hormone deficiency? 16 Glossary inside back cover “Hypo” is Greek for “below normal” or “deficient” Hypopituitarism may involve the loss of one, several or all of the pituitary hormones.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • A Radiologic Score to Distinguish Autoimmune Hypophysitis from Nonsecreting Pituitary ORIGINAL RESEARCH Adenoma Preoperatively
    A Radiologic Score to Distinguish Autoimmune Hypophysitis from Nonsecreting Pituitary ORIGINAL RESEARCH Adenoma Preoperatively A. Gutenberg BACKGROUND AND PURPOSE: Autoimmune hypophysitis (AH) mimics the more common nonsecret- J. Larsen ing pituitary adenomas and can be diagnosed with certainty only histologically. Approximately 40% of patients with AH are still misdiagnosed as having pituitary macroadenoma and undergo unnecessary I. Lupi surgery. MR imaging is currently the best noninvasive diagnostic tool to differentiate AH from V. Rohde nonsecreting adenomas, though no single radiologic sign is diagnostically accurate. The purpose of this P. Caturegli study was to develop a scoring system that summarizes numerous MR imaging signs to increase the probability of diagnosing AH before surgery. MATERIALS AND METHODS: This was a case-control study of 402 patients, which compared the presurgical pituitary MR imaging features of patients with nonsecreting pituitary adenoma and controls with AH. MR images were compared on the basis of 16 morphologic features besides sex, age, and relation to pregnancy. RESULTS: Only 2 of the 19 proposed features tested lacked prognostic value. When the other 17 predictors were analyzed jointly in a multiple logistic regression model, 8 (relation to pregnancy, pituitary mass volume and symmetry, signal intensity and signal intensity homogeneity after gadolin- ium administration, posterior pituitary bright spot presence, stalk size, and mucosal swelling) remained significant predictors of a correct classification. The diagnostic score had a global performance of 0.9917 and correctly classified 97% of the patients, with a sensitivity of 92%, a specificity of 99%, a positive predictive value of 97%, and a negative predictive value of 97% for the diagnosis of AH.
    [Show full text]
  • Acromegaly and the Surgical Treatment of Giant Nose
    ARC Journal of Clinical Case Reports Volume 3, Issue 4, 2017, PP 19-21 ISSN No. (Online) 2455-9806 DOI: http://dx.doi.org/10.20431/2455-9806.0304005 www.arcjournals.org Acromegaly and the Surgical Treatment of Giant Nose Lorna Langstaff, MBBS*, Peter Prinsley, MB ChB James Paget University Hospital, Lowestoft Road, NR31 6LA, UK *Corresponding Author: Lorna Langstaff, MBBS, James Paget University Hospital, Lowestoft Road, NR31 6LA, UK, Email: [email protected] Abstract Introduction: The endocrinological changes caused by hyperpituitarism are well managed and reversed. However, the facial changes associated with acromegaly can be permanent and cause distress and concern to patients. Case History: We present the case of an acromegalic women, previously treated for hyperpituitarism, pre- senting with persistent facial changes and a large nose. This was successfully addressed with rhinoplasty, clinical photography is provided. Discussion: The nasal changes associated with acromegaly are challenging but can be successfully treated with rhinoplasty. We discuss the few cases previously mentioned in the literature and the pathophysiology involved in the changes of facial appearance found in acromegalic patients. Keywords: Acromegaly, Giant Nose, Rhinoplasty, Hyperpituitarism Search Strategy: exp “Nasal Bone” or “Nasal Cartilages” or “Nasal Septum” or “Nasal Surgical proce- dure” and Acromegaly or Gigantism or hyperpitu* 1. INTRODUCTION 2. CASE REPORT Acromegaly characteristically causes enlarge- The patient is a 54 year old lady who presented ment of the mandible, zygomatic arches and 10 years after successful treatment for hyperpi- supraorbital ridges, as well as an enlarged nose tuitarism caused by a pituitary adenoma. The and on occasion’s nasal obstruction.
    [Show full text]
  • Pyrexia of Unknown Origin. Presenting Sign of Hypothalamic Hypopituitarism R
    Postgrad Med J: first published as 10.1136/pgmj.57.667.310 on 1 May 1981. Downloaded from Postgraduate Medical Journal (May 1981) 57, 310-313 Pyrexia of unknown origin. Presenting sign of hypothalamic hypopituitarism R. MARILUS* A. BARKAN* M.D. M.D. S. LEIBAt R. ARIE* M.D. M.D. I. BLUM* M.D. *Department of Internal Medicine 'B' and tDepartment ofEndocrinology, Beilinson Medical Center, Petah Tiqva, The Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel Summary least 10 such admissions because offever of unknown A 62-year-old man was admitted to hospital 10 times origin had been recorded. During this period, he over 12 years because of pyrexia of unknown origin. was extensively investigated for possible infectious, Hypothalamic hypopituitarism was diagnosed by neoplastic, inflammatory and collagen diseases, but dynamic tests including clomiphene, LRH, TRH and the various tests failed to reveal the cause of theby copyright. chlorpromazine stimulation. Lack of ACTH was fever. demonstrated by long and short tetracosactrin tests. A detailed past history of the patient was non- The aetiology of the disorder was believed to be contributory. However, further questioning at a previous encephalitis. later period of his admission revealed interesting Following substitution therapy with adrenal and pertinent facts. Twelve years before the present gonadal steroids there were no further episodes of admission his body hair and sex activity had been fever. normal. At that time he had an acute febrile illness with severe headache which lasted for about one Introduction week. He was not admitted to hospital and did not http://pmj.bmj.com/ Pyrexia of unknown origin (PUO) may present receive any specific therapy.
    [Show full text]
  • Genetic and Genomic Analysis of Hyperlipidemia, Obesity and Diabetes Using (C57BL/6J × TALLYHO/Jngj) F2 Mice
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Nutrition Publications and Other Works Nutrition 12-19-2010 Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P. Stewart Marshall University Hyoung Y. Kim University of Tennessee - Knoxville, [email protected] Arnold M. Saxton University of Tennessee - Knoxville, [email protected] Jung H. Kim Marshall University Follow this and additional works at: https://trace.tennessee.edu/utk_nutrpubs Part of the Animal Sciences Commons, and the Nutrition Commons Recommended Citation BMC Genomics 2010, 11:713 doi:10.1186/1471-2164-11-713 This Article is brought to you for free and open access by the Nutrition at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Nutrition Publications and Other Works by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. Stewart et al. BMC Genomics 2010, 11:713 http://www.biomedcentral.com/1471-2164/11/713 RESEARCH ARTICLE Open Access Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice Taryn P Stewart1, Hyoung Yon Kim2, Arnold M Saxton3, Jung Han Kim1* Abstract Background: Type 2 diabetes (T2D) is the most common form of diabetes in humans and is closely associated with dyslipidemia and obesity that magnifies the mortality and morbidity related to T2D. The genetic contribution to human T2D and related metabolic disorders is evident, and mostly follows polygenic inheritance. The TALLYHO/ JngJ (TH) mice are a polygenic model for T2D characterized by obesity, hyperinsulinemia, impaired glucose uptake and tolerance, hyperlipidemia, and hyperglycemia.
    [Show full text]
  • A Case of Congenital Central Hypothyroidism Caused by a Novel Variant (Gln1255ter) in IGSF1 Gene
    Türkkahraman D et al. A Novel Variant in IGSF1 Gene CASE REPORT DO I: 10.4274/jcrpe.galenos.2020.2020.0149 J Clin Res Pediatr Endocrinol 2021;13(3):353-357 A Case of Congenital Central Hypothyroidism Caused by a Novel Variant (Gln1255Ter) in IGSF1 Gene Doğa Türkkahraman1, Nimet Karataş Torun2, Nadide Cemre Randa3 1University of Health Sciences Turkey, Antalya Training and Research Hospital, Clinic of Pediatric Endocrinology, Antalya, Turkey 2University of Healty Sciences Turkey, Antalya Training and Research Hospital, Clinic of Pediatrics, Antalya, Turkey 3University of Healty Sciences Turkey, Antalya Training and Research Hospital, Clinic of Medical Genetics, Antalya, Turkey What is already known on this topic? Mutations in the immunoglobulin superfamily, member 1 (IGSF1) gene that mainly regulates pituitary thyrotrope function lead to X-linked hypothyroidism characterized by congenital hypothyroidism of central origin and testicular enlargement. The clinical features associated with IGSF1 mutations are variable, but prolactin and/or growth hormone deficiency, and discordance between timing of testicular growth and rise of serum testosterone levels could be seen. What this study adds? Genetic analysis revealed a novel c.3763C>T variant in the IGSF1 gene. To our knowledge, this is the first reported case of IGSF1 deficiency from Turkey. Additionally, as in our case, early testicular enlargement but delayed testosterone rise should be evaluated in all boys with central hypothyroidism, as macro-orchidism is usually seen in adulthood. Abstract Loss-of-function mutations in the immunoglobulin superfamily, member 1 (IGSF1) gene cause X-linked central hypothyroidism, and therefore its mutation affects mainly males. Central hypothyroidism in males is the hallmark of the disorder, however some patients additionally present with hypoprolactinemia, transient and partial growth hormone deficiency, early/normal timing of testicular enlargement but delayed testosterone rise in puberty, and adult macro-orchidism.
    [Show full text]
  • Hyperprolactinaemia Common and Treatable
    cardiology, and 8 Asherson RA, Harris EN, Gharavi AE, Hughes GRV. Systemic lupus erythematosus, anti- haematology, neurology, rheumatology phospholipid antibodies, chorea, and oral contraceptives. Arthritis Rheum 1986;29:1535-6. clinics as well as in obstetrics. 9 Asherson RA, Chan JKH, Harris EN, Gharavi AE, Hughes GRV. Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal. Ann Rheum Dis 1985;44:823-5. Treatment depends on careful anticoagulation, but the 10 Asherson RA, Lanham J, Hull RG, Boev ML, Gharavi AE, Hughes GRV. Renal vein thrombosis in value of steroids, immunosuppressive agents, and plasma systemic lupus erythematosus: association with the "lupus anticoagulant." Clin Exp Rheumatol 1984;2:75-9. exchange is still not clear. In obstetrics, although claims 11 Hughes GRV, Mackworth-Young CG, Harris EN, Gharavi AE. Veno-occlusive disease in systemic BMJ: first published as 10.1136/bmj.297.6650.701 on 17 September 1988. Downloaded from of therapeutic success with various anticoagulation or lupus erythematosus: possible association with anticardiolipin antibodies? Arthritis Rheum 1984;27: 107 1. immunosuppressive regimens increase each year, the data 12 Asherson RA, Mackworth-Young C, Boey ML, et al. Pulmonary hypertension in systemic lupus remain anecdotal and the overall results poor. erythematosus. Br Med] 1983;287:1024-5. 13 Harris EN, Gharavi AE, Asherson RA, Boey ML, Hughes GRV. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol 1984;2:47-5 1. GRAHAM R V HUGHES 14 Asherson RA, Mackay IR, Harris EN. Myocardial infarction in a young male with systemic lupus Consultant Rheumatologist, erythematosus, deep vein thrombosis, and antibodies to phospholipid.
    [Show full text]